Are sodium-glucose cotransporter-2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation

J Diabetes. 2024 Jul;16(7):e13570. doi: 10.1111/1753-0407.13570.

Abstract

Highlights A persistent glycosuria alongside hypoglycemia in pediatric type 1 diabetes mellitus needs further evaluation. Morning hypoglycemia is a limiting side effect of sodium glucose transporter 2 (SGLT2) inhibitors in children younger than 5 years old. SLC5A2 mutation functioning as a SGLT2 inhibitor can result in acceptable range of glycated hemoglobin in younger children and lower required doses of insulin.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Blood Glucose / analysis
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Child, Preschool
  • Diabetes Mellitus, Type 1* / drug therapy
  • Diabetes Mellitus, Type 1* / genetics
  • Drug Therapy, Combination
  • Female
  • Glycated Hemoglobin / analysis
  • Glycated Hemoglobin / metabolism
  • Humans
  • Hypoglycemia / chemically induced
  • Hypoglycemia / genetics
  • Hypoglycemic Agents* / therapeutic use
  • Insulin* / therapeutic use
  • Male
  • Mutation*
  • Sodium-Glucose Transporter 2 Inhibitors* / adverse effects
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
  • Sodium-Glucose Transporter 2* / genetics

Substances

  • Sodium-Glucose Transporter 2 Inhibitors
  • Sodium-Glucose Transporter 2
  • SLC5A2 protein, human
  • Insulin
  • Hypoglycemic Agents
  • Blood Glucose
  • Glycated Hemoglobin